Bio-Techne TECH NASDAQ · Healthcare · United States
$72.80 -0.05% -$0.04
Summary
55 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 14 USD is left as net profit.
- It holds more cash than debt: $350.0M against $285.6M.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue grew by only 2.2% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 66.5 USD for 1 USD of yearly profit. Over the last five years it was 68.0 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 5.5% a year over 5 years. Over the last 3 years it grew by 2.2% a year. For the next fiscal year analysts expect revenue to grow by 4.7%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 34 USD
- Research and development 7.9 USD
- Sales and administration 38 USD
- Taxes and other 5.6 USD
- Net profit 14 USD
Net profit, industry median (Biotechnology) -11 USD
Out of every 100 USD of revenue, 14 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.44%
- Paid out of profit
- 29%
You receive $0.32 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Neutral- Buy 12
- Hold 14
- Sell 0
Today's price within the analysts' price targets
The average target of $65.78 is 9.6% below today's price. 46% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2026By product
- Consumables 88%
- Instruments 9.9%
- Royalty 2.2%
By region
- U S 52%
- Europe 24%
- C N 8.6%
- APAC, excluding Greater China 7.1%
- UNITED KINGDOM 4.6%
- Other 3.2%
Consumables brings in 88% of revenue. Royalty grew fastest, by 5.8% a year.
Segments in detail